Lydia Jasmin Hanisch

This inventor holds 11 USPTO granted patents and 7 published patent applications, plus 2 CIPO patents and 4 EPO patents. Top assignees: Hoffmann-La Roche Inc., Engmab Ag, Engmab Sarl. Active years: 2019-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Lydia Jasmin Hanisch. Retrieved from https://idiyas.com/inventor/lydia-jasmin-hanisch

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 11 (Patent Applications = 7)

% Patents Active = 100.0

CIPO Patents = 2 (Patent Applications = 3)

EPO Patents = 4 (Patent Applications = 9)

Average Co-Inventor Count = 10.2

ph-index = 2

Forward Citations = 13(Granted Patents)

Location History:

Birmensdorf, CH (2019 - 2024)
Schlieren, CH (2021 - 2024)

Company Filing History:

7 out of 5,026

Hoffmann-La Roche Inc.

where one patent can have more than one assignee

Years Active: 2019-2026

Loading Chart...

11 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12637522 - MONOCLONAL ANTIBODIES AGAINST BCMA (2026-05-26),

2. 12098213 - Antibodies binding to HLA-A2/WT1 (2024-09-24),

3. 12038441 - CAR-T reporter based diagnostic assays to detect tumor antigens in cancer patients (2024-07-16),

4. 12000064 - Universal reporter cell assay for specificity test of novel antigen binding moieties (2024-06-04),

5. 11987632 - Antibodies binding to HLA-A2/MAGE-A4 (2024-05-21),

6. 11788205 - Car-t cell assay for specificity test of novel antigen binding moieties (2023-10-17),

7. 11787873 - Bispecific HER2 antibodies and methods of use (2023-10-17),

8. 11192957 - Antibodies binding to HLA-A2/WT1 (2021-12-07),

9. 10683369 - Monoclonal antibodies against BCMA (2020-06-16),

10. 10584178 - Bispecific HER2 antibodies and methods of use (2020-03-10),

11. 10253104 - Bispecific antibodies against CD3ϵ and BCMA (2019-04-09),

Title: Lydia Jasmin Hanisch: Innovator in Cancer Diagnostics and Therapeutics

Introduction

Lydia Jasmin Hanisch is a prominent inventor based in Birmensdorf, Switzerland. She has made significant contributions to the field of cancer diagnostics and therapeutics, holding a total of 10 patents. Her work focuses on innovative solutions that enhance the detection and treatment of cancer.

Latest Patents

One of her latest patents is titled "Antibodies binding to HLA-A2/WT1." This invention relates to antibodies that bind to HLA-A2/WT1, including bispecific antigen binding molecules designed for activating T cells. The patent also covers polynucleotides encoding such antibodies, as well as vectors and host cells that comprise these polynucleotides. Furthermore, it outlines methods for producing the antibodies and their applications in disease treatment. Another significant patent is "CAR-T reporter based diagnostic assays to detect tumor antigens in cancer patients." This invention pertains to diagnostic assays utilizing cell cultures, specifically chimeric antigen receptor (CAR) expressing reporter cell assays. These assays analyze patient samples to diagnose cancer by quantifying tumor antigen expression and predicting clinical responses to cancer immunotherapies. The invention aims to improve the safety of cancer immunotherapies.

Career Highlights

Lydia has worked with notable companies such as Hoffmann-La Roche Inc. and Engmab AG. Her experience in these organizations has contributed to her expertise in the field of biotechnology and pharmaceuticals.

Collaborations

Throughout her career, Lydia has collaborated with esteemed colleagues, including Christian Klein and Ekkehard Moessner. These partnerships have fostered innovation and advancement in her research endeavors.

Conclusion

Lydia Jasmin Hanisch is a trailblazer in the realm of cancer diagnostics and therapeutics. Her innovative patents and collaborations reflect her commitment to improving patient outcomes in the fight against cancer.

Profile summary based on public USPTO records.